139 related articles for article (PubMed ID: 24794897)
1. A new injectable liquid crystal system for one month delivery of leuprolide.
Ki MH; Lim JL; Ko JY; Park SH; Kim JE; Cho HJ; Park ES; Kim DD
J Control Release; 2014 Jul; 185():62-70. PubMed ID: 24794897
[TBL] [Abstract][Full Text] [Related]
2. An injectable liquid crystal system for sustained delivery of entecavir.
Lim JL; Ki MH; Joo MK; An SW; Hwang KM; Park ES
Int J Pharm; 2015 Jul; 490(1-2):265-72. PubMed ID: 26004002
[TBL] [Abstract][Full Text] [Related]
3. The in vivo transformation and pharmacokinetic properties of a liquid crystalline drug delivery system.
Otte A; Báez-Santos YM; Mun EA; Soh BK; Lee YN; Park K
Int J Pharm; 2017 Oct; 532(1):345-351. PubMed ID: 28844902
[TBL] [Abstract][Full Text] [Related]
4. Formulation and characterization of a liquid crystalline hexagonal mesophase region of phosphatidylcholine, sorbitan monooleate, and tocopherol acetate for sustained delivery of leuprolide acetate.
Báez-Santos YM; Otte A; Mun EA; Soh BK; Song CG; Lee YN; Park K
Int J Pharm; 2016 Nov; 514(1):314-321. PubMed ID: 27863678
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
6. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
7. Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate.
Okada H; Doken Y; Ogawa Y
J Pharm Sci; 1996 Oct; 85(10):1044-8. PubMed ID: 8897268
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
[TBL] [Abstract][Full Text] [Related]
9. A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.
Lim CN; Salem AH
Clin Pharmacokinet; 2015 Sep; 54(9):963-73. PubMed ID: 25791895
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics and pharmacodynamics of two leuprolide acetate 45 mg 6-month depot formulations in patients with prostate cancer.
Mostafa NM; Chwalisz K; Larsen L; Mattia-Goldberg C; Spitz A; Pradhan RS
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):270-5. PubMed ID: 27128832
[TBL] [Abstract][Full Text] [Related]
11. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references.
Leitner JM; Mayr FB; Spiel AO; Firbas C; Savulsky C; Mis R; Corrado ME; Jilma B
Int J Clin Pharmacol Ther; 2008 Aug; 46(8):407-14. PubMed ID: 18793582
[TBL] [Abstract][Full Text] [Related]
13. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits.
Singh S; Singh J
Int J Pharm; 2007 Jan; 328(1):42-8. PubMed ID: 16959451
[TBL] [Abstract][Full Text] [Related]
14. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.
Ravivarapu HB; Moyer KL; Dunn RL
AAPS PharmSciTech; 2000 Feb; 1(1):E1. PubMed ID: 14727850
[TBL] [Abstract][Full Text] [Related]
15. A study of microemulsions as prolonged-release injectables through in-situ phase transition.
Wu Z; Alany RG; Tawfeek N; Falconer J; Zhang W; Hassan IM; Rutland M; Svirskis D
J Control Release; 2014 Jan; 174():188-94. PubMed ID: 24316265
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
17. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
Zheng JY; Fulu MY
Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
[TBL] [Abstract][Full Text] [Related]
18. First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs.
Plourde F; Motulsky A; Couffin-Hoarau AC; Hoarau D; Ong H; Leroux JC
J Control Release; 2005 Nov; 108(2-3):433-41. PubMed ID: 16182402
[TBL] [Abstract][Full Text] [Related]
19. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
[TBL] [Abstract][Full Text] [Related]
20. [Design and development of controlled release of drugs from injectable microcapsules].
Takada S; Ogawa Y
Nihon Rinsho; 1998 Mar; 56(3):675-9. PubMed ID: 9549355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
